MCRB - Seres Therapeutics GAAP EPS of -$0.37 beats by $0.13 revenue of $0.31M misses by $0.54M
2023-11-02 08:10:36 ET
More on Seres Therapeutics
- Seres: VOWST Is A Great Product But Commercialization Prospects Unclear Due To Very High Price
- Seres Therapeutics: Approved Drug And Nestle Partnership Make It A Buy
- Seres Therapeutics, Inc. (MCRB) Q2 2023 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on Seres Therapeutics
- Historical earnings data for Seres Therapeutics
For further details see:
Seres Therapeutics GAAP EPS of -$0.37 beats by $0.13, revenue of $0.31M misses by $0.54M